Patent ID: 9068231
Filing Date: 2015-06-30
Classification: A61P,C12N,C12Q,G01N

Abstract:
1. An in vitro method for screening a compound capable of inhibiting the binding of GSK-3β with galectin-3 and down-regulating the expression of fascin-1 in gastric cancer cells, comprising: a) treating gastric cancer cells with a candidate agent; b) measuring (i) binding of galectin-3 with glycogen synthetase kinase-3β (GSK-3β) in the nucleus of the gastric cancer cell treated with the candidate agent, and (ii) expression level of fascin-1 in the gastric cancer cells treated with the candidate agent; and c) identifying a candidate agent as the compound when the binding of galectin-3 and GSK-3β in the nucleus measured in step b)(i), and the expression level of fascin-1 measured in step b)(ii) are reduced in the gastric cancer cells as compared to the gastric cancer cells before treatment with the candidate agent, wherein the candidate agent is a galectin-3 siRNA.